Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02915744 · ClinicalTrials.gov registry record · Phase 3
A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
A Phase 3 study of Breast Cancer and Metastasis, sponsored by Nektar Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 178
- Enrollment target
- 20
- Study locations
NCT02915744 is a Phase 3 study of Breast Cancer and Metastasis that has completed, run by Nektar Therapeutics. The registered enrollment target is 178 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The trial reports 20 study locations across 16 states.
The verdict
NCT02915744, a Phase 3 study of Breast Cancer and Metastasis, has completed, sponsored by Nektar Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 178 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated with an anthracycline, a taxane, and capecitabine in either the adjuvant or metastatic setting (prior anthracycline may be omitted if medically appropriate or contraindicated for the patient).
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG Eribulin
- DRUG Vinorelbine
- DRUG Ixabepilone
- DRUG NKTR-102
Study Locations (20)
Florida
- Investigator Site - Miami - Miami
- Investigator Site - Plantation - Plantation
- Investigator Site - West Palm Beach - West Palm Beach
California
- Investigator Site - Orange - Orange
- Investigator Site - San Francisco - San Francisco
Texas
- Investigator Site - Fort Worth - Fort Worth
- Investigator Site - Houston - Houston
Arizona
- Investigator Site - Tucson - Tucson
Georgia
- Investigator Site - Athens - Athens
Maryland
- Investigator Site - Baltimore - Baltimore
Massachusetts
- Investigator Site - Boston - Boston
Minnesota
- Investigator Site - Minneapolis - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2016-11 |
| Est. Completion | 2020-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02915744
The ClinicalTrials.gov registry entry for NCT02915744 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (94% lower). The listed sponsor is Nektar Therapeutics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Gemcitabine is the first listed.
NCT02915744 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Florida, California, Texas.
Frequently Asked Questions
What is clinical trial NCT02915744 about?
NCT02915744 is a clinical study titled "A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine". This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated with an anthracycline, a taxane, and capecitabine in either the adjuvant o...
What is the current status of trial NCT02915744?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 178 participants. The study started on 2016-11. Estimated completion is 2020-07.
What conditions does trial NCT02915744 study?
This clinical trial studies the following conditions: Breast Cancer, Metastasis.
What interventions are being tested in trial NCT02915744?
The interventions under investigation include: Gemcitabine (DRUG), Eribulin (DRUG), Vinorelbine (DRUG), Ixabepilone (DRUG), NKTR-102 (DRUG).
Who is sponsoring clinical trial NCT02915744?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02915744 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.